• 1454 Citations
  • 22 h-Index
19972019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Argun Akcakanat is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Sirolimus Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Triple Negative Breast Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Phosphatidylinositol 3-Kinases Medicine & Life Sciences
Heterografts Medicine & Life Sciences
Paclitaxel Medicine & Life Sciences
Stearoyl-CoA Desaturase Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1997 2019

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer

Owusu-Brackett, N., Evans, K. W., Akcakanat, A., Yuca, E., Tapia, C., Rizvi, Y. Q., Ileana Dumbrava, E. E., Janku, F. & Meric-Bernstam, F., Jan 1 2019, In : Oncotarget. 10, 49, p. 5011-5019 9 p.

Research output: Contribution to journalArticle

eribulin
Triple Negative Breast Neoplasms
Heterografts
Cell Line
Phosphatidylinositol 3-Kinase
13 Citations (Scopus)

A population of heterogeneous breast cancer patient-derived xenografts demonstrate broad activity of PARP inhibitor in BRCA1/2 wild-type tumors

Evans, K. W., Yuca, E., Akcakanat, A., Scott, S. M., Arango, N. P., Zheng, X., Chen, K., Tapia, C., Tarco, E., Eterovic, A. K., Black, D. M., Litton, J. K., Yap, T. A., Tripathy, D., Mills, G. B. & Meric-Bernstam, F., Nov 1 2017, In : Clinical Cancer Research. 23, 21, p. 6468-6477 10 p.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
Heterografts
Breast Neoplasms
Protein Array Analysis
Phosphatidylinositol 3-Kinases

Modeling breast cancer heterogeneity with patient-derived xenografts

Evans, K. W., Paez-Arango, N., Akcakanat, A., Yuca, E. & Meric-Bernstam, F., Jan 1 2017, Patient Derived Tumor Xenograft Models: Promise, Potential and Practice. Elsevier Inc., p. 243-256 14 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

Heterografts
Breast Neoplasms
Genetic Drift
Neoplasms
Transplants
6 Citations (Scopus)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

Arango, N. P., Yuca, E., Zhao, M., Evans, K. W., Scott, S., Kim, C., Gonzalez-Angulo, A. M., Janku, F., Ueno, N. T., Tripathy, D., Akcakanat, A., Naing, A. & Meric-Bernstam, F., Aug 15 2017, In : Breast Cancer Research. 19, 1, 93.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
eribulin
Neoplasms
Cell Line
Inhibitory Concentration 50
1 Citation (Scopus)

Erratum: Ability to generate patient-derived breast cancer xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes (PLoS ONE (2015) 10:9 (e0136851) DOI: 10.1371/journal.pone.0136851)

McAuliffe, P. F., Evans, K. W., Akcakanat, A., Chen, K., Zheng, X., Zhao, H., Eterovic, A. K. B., Sangai, T., Holder, A. M., Sharma, C., Chen, H., Do, K-A., Tarco, E., Gagea Iurascu, M., Naff, K. A., Sahin, A. A., Multani, A. S., Black, D. M., Mittendorf, E. A., Bedrosian, I. & 3 others, Mills, G. B., Gonzalez-Angulo, A. M. & Meric-Bernstam, F., Mar 1 2016, In : PloS one. 11, 3, e0151121.

Research output: Contribution to journalComment/debate

Heterografts
breast neoplasms
Breast Neoplasms